<DOC>
	<DOCNO>NCT02293694</DOCNO>
	<brief_summary>The feasibility Sayana Press self-injection potential practice increase contraceptive continuation never assess family planning program low-resource setting . The Malawi Ministry Health ( MOH ) United States Agency International Development ( USAID ) Malawi Mission request Advancing Partners Communities ( APC ) project assess self-injection Sayana Press inform decision-making procurement Sayana Press distribution health system Malawi .</brief_summary>
	<brief_title>Sayana® Press Self-injection Study Malawi</brief_title>
	<detailed_description>Sayana® Press subcutaneous formulation depot medroxyprogesterone acetate ( DMPA ) prefilled , auto-disabled injection system call Uniject ( Pfizer , Inc. , USA ) . Sayana Press register Medicines Health Care Products Regulatory Agency ( MHRA ) several national regulatory agency . The addition method anticipate aid improve provision family planning service low-resource setting . As , Sayana Press could particularly useful country Malawi injectable contraception common method use . DMPA client provider ready explore potential self-injection Sayana Press . A study conduct large family planning clinic Edinburgh , Scotland find self-administration DMPA-SC feasible associate similar continuation rate satisfaction clinician-administered DMPA-IM . A non-comparison study conduct Planned Parenthood clinic Florida find continuation self-injected DMPA-SC high ( 74 % ) fourth injection . Participants study report injection easy convenient likely recommend self-administration woman . Moreover , September 29 , 2014 Pfizer submit request MHRA change Sayana Press label include self-injection . If self-injection find feasible , result research inform self-injection training material , message provider client , future scale-up effort Malawi elsewhere sub-Saharan Africa .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Age 1840 , inclusive In general good health ( participant verbally report feel well ) Able understand willing sign inform consent document Willing give contact information followup Agree followup visits/interviews Willing randomized selfinjection arm provideradministered injection arm Menstrual period start within past 7 day ( new DMPA user ) Meet eligibility criterion receive DMPA per WHO Medical Eligibility Criteria ( MEC ) Pregnancy Plans become pregnant next 12 month Plans relocate outside study area next 12 month Any condition ( social medical ) opinion investigator would make study participation unsafe would interfere adherence study requirement complicate data interpretation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>DMPA-SC : depo medroxyprogesterone acetate sub-cutaneous</keyword>
	<keyword>DMPA-IM : depo medroxyprogesterone acetate intramuscular</keyword>
</DOC>